Nama's AI scorecard currently rates Integra LifeSciences Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is IART's P/E ratio?

Integra LifeSciences trades at a trailing price-to-earnings ratio of 5.3.

When does IART report earnings?

Integra LifeSciences's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.64.

What is the IART price target?

The median analyst price target from 9 analysts is $14.00, with a range of $13.00 – $23.00.

Is IART Shariah compliant?

Nama's AAOIFI-style screen reads Integra LifeSciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Integra LifeSciences (IART)

Healthcare · Medical Devices · NASDAQ

Integra LifeSciences (IART) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.04B, a trailing price-to-earnings ratio of 5.3 and a free-cash-flow yield of -4.4%. Over the most recent reported fiscal year, revenue grew 1.5% and free cash flow per share fell 403.4%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +15.9% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-81.7%

How far the last close sits under the highest price of the past five years.

Market cap	$1.04B
Trailing P/E	5.3
Price / book	0.4
Price / sales	0.6
FCF yield	-4.4%
Dividend yield	—
Gross margin	52.4%
Operating margin	4.4%
Net margin	0.8%
Revenue growth (YoY)	+1.5%
Revenue growth (3-yr annual)	+1.6%
EPS growth (YoY)	-12.9%
FCF/share growth (YoY)	-403.4%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

IART earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.64). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 21, 2026	$0.59	$0.56	+5.4%	$411.18M
Q2 2026	Jul 29, 2026	$0.56	$0.48	+16.7%	$418.76M
Q1 2026	May 5, 2026	$0.54	$0.40	+35.0%	$391.92M
Q4 2025	Feb 26, 2026	$0.83	$0.80	+3.8%	$434.93M

IART analyst price target

Median target $14.00 from 9 analysts, ranging $13.00 – $23.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live IART data on Nama Insights →

Recent Congressional trades

Integra LifeSciences trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 9, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	May 15, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Nov 11, 2023
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

IART FAQ

Is IART a buy?: Nama's AI scorecard currently rates Integra LifeSciences Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is IART's P/E ratio?: Integra LifeSciences trades at a trailing price-to-earnings ratio of 5.3.
When does IART report earnings?: Integra LifeSciences's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.64.
What is the IART price target?: The median analyst price target from 9 analysts is $14.00, with a range of $13.00 – $23.00.
Is IART Shariah compliant?: Nama's AAOIFI-style screen reads Integra LifeSciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.